Abstract:We report the development of novel cannabinergic probes that can stabilize the cannabinoid receptors (CBRs) through tight binding interactions. Ligand design involves the introduction of select groups at a judiciously chosen position within the classical hexahydrocannabinol template (monofunctionalized probes). Such groups include the electrophilic isothiocyanato, the photoactivatable azido, and the polar cyano moieties. These groups can also be combined to produce bifunctionalized probes potentially capable of interacting at two distinct sites within the CBR-binding domains. These novel compounds display remarkably high binding affinities for CBRs and are exceptionally potent agonists. A key ligand (27a, AM11245) exhibits exceptionally high potency in both in vitro and in vivo assays and was designated as "megagonist," a property attributed to its tight binding profile. By acting both centrally and peripherally, 27a distinguishes itself from our previously reported "megagonist" AM841, whose functions are restricted to the periphery.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c02053?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02053</a>.Experimental procedures, spectroscopic, analytical, and physical data for 12a–b, 13a–b, 14a–c, 15a–c, 16a–c, 17a–c, 18a–c, 19a–c, 20a–c, 21a–c, 22a–c, 23a–c, 24a–c, 25a–c, 26a–c, and 27a–c; saturation binding curves using [3H]CP-55,940 for CB1 and CB2 receptors pre-incubated with the 25a–c, 26a–c, 27a–c, 31c, 32c, 33c, and 34c; and HPLC traces of 25a, 26c, 27b, and 31c (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02053/suppl_file/jm0c02053_si_001.pdf">PDF</a>).Molecular formula strings and biochemical data of 25a–c, 26a–c, 27a–c, 31c, 32c, 33c, and 34c (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02053/suppl_file/jm0c02053_si_002.csv">CSV</a>)This article has not yet been cited by other publications.

Structure–Affinity Relationships and Structure–Kinetic Relationships of 1,2-Diarylimidazol-4-carboxamide Derivatives as Human Cannabinoid 1 Receptor Antagonists

Design, Synthesis, And Sar Studies Of Heteroarylpyrimidines And Heteroaryltriazines As Cb2r Ligands

Design, syntheses, structure-activity relationships and docking studies of coumarin derivatives as novel selective ligands for the CB2 receptor.

Crystal Structure of the Human Cannabinoid Receptor CB1

Novel Functionalized Cannabinoid Receptor Probes: Development of Exceptionally Potent Agonists

Motifs in Natural Products as Useful Scaffolds to Obtain Novel Benzo[ d]imidazole-Based Cannabinoid Type 2 (CB2) Receptor Agonists

Structure activity relationship studies of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan (NAQ) analogues as potent opioid receptor ligands: preliminary results on the role of electronic characteristics for affinity and function.

Crystal Structure of the Human Cannabinoid Receptor CB2

Large library docking for cannabinoid-1 receptor agonists with reduced side effects

In silico investigation of interactions between human cannabinoid receptor-1 and its antagonists

Ligand-specific homology modeling of human cannabinoid (CB1) receptor

Pharmacological evaluation of new constituents of "Spice": synthetic cannabinoids based on indole, indazole, benzimidazole and carbazole scaffolds

Structure selectivity relationship studies of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan derivatives toward the development of the mu opioid receptor antagonists.

Structural Characteristics of Cannabinoid Type I Receptor Antagonists

Rational design of cannabinoid type-1 receptor allosteric modulators: Org27569 and PSNCBAM-1 hybrids

Structure activity relationship studies of natural product chemokine receptor CCR5 antagonist anibamine toward the development of novel anti prostate cancer agents.

Modulating the affinity and signaling bias of cannabinoid receptor 1 antagonists

Modeling, Molecular Dynamics Simulation, and Mutation Validation for Structure of Cannabinoid Receptor 2 Based on Known Crystal Structures of GPCRs

Flipping the GPCR Switch: Structure-Based Development of Selective Cannabinoid Receptor 2 Inverse Agonists

A homology modeling study toward the understanding of three-dimensional structure and putative pharmacological profile of the G-protein coupled receptor GPR55.

Computational Investigation on the Binding Modes of Rimonabant Analogs with CB1 and CB2